Condition: Preeclampsia · Preterm Birth · Pregnancy Complications · Sponsor: CHU de Quebec-Universite Laval
The Biobank includes data and biological specimens of women from three original studies: 1) First-trimester Prediction of Preeclampsia (PREDICTION Study, NCT02189148), 2) Pre-Eclampsia And growth Retardation, an evaluative Longitudinal study (PEARL Study, NCT02379832), 3) Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial (NCT02280031) and 4)PREDICTION2: Prediction of Preeclampsia and other Pregnancy Complications Following Combined Iterative Screening.
This description comes directly from the study's public registry record.
Emmanuel Bujold, MD, MSc · 418-525-4444 · emmanuel.bujold@crchudequebec.ulaval.ca
Sylvie Tapp, MSc · 418-525-4444 · sylvie.tapp@crchudequebec.ulaval.ca
Always discuss trial participation with your own doctor first.
| CHU de Quebec | Québec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02744365